⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11156551 | 0.74 | ADH1B (0.62) | — | |
| SCHEMBL1917 | 0.74 | — | — | |
| SCHEMBL6435190 | 0.74 | — | — | |
| Iodide SCHEMBL7773718 | 0.71 | — | — | |
| SCHEMBL28454188 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL28980438 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL3962157 | 0.71 | — | — | |
| SCHEMBL23231050 | 0.69 | — | — | |
| SCHEMBL10785431 | 0.69 | ADH1B (0.56) | — | |
| SCHEMBL6036724 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354448-B2 | Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes | METABOLEX, INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-8329749-B2 | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia | METABOLEX, INC. (US) | 2012-12-11 | — | — | US | claimed |
| US-8481597-B2 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8354448-B2 | Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes | METABOLEX, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8329749-B2 | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia | METABOLEX, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225940-A1 | Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia | DIATEX, INC. | 2012-09-06 | — | — | US | disclosed |
| EP-1614418-B1 | use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia | METABOLEX INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093855-A1 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA | METABOLEX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093853-A1 | USE OF (-)(3-TRIHALOMETHYLPHENOXY)(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERLIPIDEMIA | METABOLEX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7576131-B2 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070270490-A1 | USE OF (-)(3-TRIHALOMETHYLPHENOXY)(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERLIPIDEMIA | METABOLEX, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-6646004-B1 | Administering antidiabetic agents such as 2-acetamidoethyl-4-chlorophenyl-(3-trifluoromethylphenoxy)acetate, having side effect reduction | METABOLEX, INC. | 2003-11-11 | — | — | US | disclosed |
| US-6624194-B1 | 3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. Provides (3-trihalomethylphenoxy) (4-halophenyl) acetic acid for | METABOLEX, INC. | 2003-09-23 | — | — | US | disclosed |
| US-6613802-B1 | Composition containing (-) enantiomer of compound in enantiomeric excess of at least 80% relative to (+) enantiomer, which exhibits reduced inhibition of cytochrome P450 2C9 | METABOLEX, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-1183020-A2 | USE OF(-)(3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL)ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6262118-B1 | THERAPY OF TYPE 2 DIABETES IN A MAMMAL BY ADMINISTERING (-) 4-CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY)ACETIC ACID DERIVATIVE | METABOLEX, INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2000074666-A2 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-0382213-B1 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMA CO LTD (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-5053548-A | Containing hydroxy substituents; nervous system disorders | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0382213-A2 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |